N@N

Incyte Appoints Wendy Dixon, Ph.D., to Its Board of Directors

^{Published on 2010-05-25 13:35:20 - Market Wire}
 

WILMINGTON, Del.--([ BUSINESS WIRE ])--Incyte Corporation (Nasdaq:INCY) announced that Wendy Dixon, Ph.D., former Chief Marketing Officer and President, Global Marketing at Bristol-Myers Squibb Company (BMS), has joined Incytea™s board of directors.

"Dr. Dixona™s strong technical background, combined with direct experience in building successful marketing and sales teams and commercializing new pharmaceutical products, will be of great value as we prepare for the potential launch of our first product"

Dr. Dixona™s qualifications and prior experience include 30 years in the biopharmaceutical industry involving multiple product launches and new drug approvals across a broad range of therapeutic areas, the establishment of successful commercial organizations in the U.S. and Europe that led to a number of multibillion dollar global brands, and the effective integration of research and development, clinical, marketing, manufacturing and regulatory programs to achieve rapid development of competitive new products.

aDr. Dixona™s strong technical background, combined with direct experience in building successful marketing and sales teams and commercializing new pharmaceutical products, will be of great value as we prepare for the potential launch of our first product,a stated Paul A. Friedman, M.D., Incytea™s President and Chief Executive Officer. aHer involvement in all aspects of drug development, including the prioritization of product portfolios, will also be important as we work to maximize the value of Incytea™s broad maturing pipeline for our key stakeholders.a

In addition to her prior role at BMS, Dr. Dixon has held senior management, marketing, business development and regulatory affairs positions at Merck, Osteotech, Centocor and SmithKline & French (now a part of GlaxoSmithKline). She is also on the board of directors of Orexigen Therapeutics, DENTSPLY and Furiex Pharmaceuticals and serves as a strategic advisor for The Monitor Group, a privately-owned global management consulting firm.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based drug discovery and development company focused on developing proprietary small molecule drugs for oncology and inflammation. Incyte's most advanced compound, INCB18424, is in Phase III development for myelofibrosis. For additional information on Incyte, visit the Company's web site at [ www.incyte.com ].